HK1205137A1 - 生產型細胞系的增強子 - Google Patents

生產型細胞系的增強子

Info

Publication number
HK1205137A1
HK1205137A1 HK15105590.6A HK15105590A HK1205137A1 HK 1205137 A1 HK1205137 A1 HK 1205137A1 HK 15105590 A HK15105590 A HK 15105590A HK 1205137 A1 HK1205137 A1 HK 1205137A1
Authority
HK
Hong Kong
Prior art keywords
cell line
production cell
line enhancers
enhancers
production
Prior art date
Application number
HK15105590.6A
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1205137A1 publication Critical patent/HK1205137A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
HK15105590.6A 2012-05-29 2015-06-12 生產型細胞系的增強子 HK1205137A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers
PCT/US2013/043116 WO2013181253A1 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (1)

Publication Number Publication Date
HK1205137A1 true HK1205137A1 (zh) 2015-12-11

Family

ID=49670701

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105590.6A HK1205137A1 (zh) 2012-05-29 2015-06-12 生產型細胞系的增強子

Country Status (21)

Country Link
US (9) US9079954B2 (zh)
EP (3) EP4219546A3 (zh)
JP (5) JP6298455B2 (zh)
KR (4) KR102346867B1 (zh)
CN (2) CN104350068B (zh)
AU (4) AU2013267525B2 (zh)
BR (1) BR112014029095A2 (zh)
CA (1) CA2873131A1 (zh)
DK (1) DK2875047T3 (zh)
EA (2) EA201792213A1 (zh)
ES (1) ES2940900T3 (zh)
FI (1) FI2875047T3 (zh)
HK (1) HK1205137A1 (zh)
HU (1) HUE061479T2 (zh)
IL (3) IL235573B (zh)
MX (1) MX360359B (zh)
PL (1) PL2875047T3 (zh)
SG (2) SG11201407652RA (zh)
TW (2) TW201823460A (zh)
WO (1) WO2013181253A1 (zh)
ZA (1) ZA201408289B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
TWI827531B (zh) 2016-04-20 2024-01-01 美商再生元醫藥公司 基於使用增強表現基因座之製備抗體的組成物及方法
JP7134868B2 (ja) 2016-04-20 2022-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 発現強化座位の使用に基づく抗体を作製するための組成物および方法
EP3532497A4 (en) * 2016-10-26 2020-05-13 The Board of Trustees of the Leland Stanford Junior University MODIFIED IMMUNOGLOBULIN BAND REGIONS TO REDUCE HEMAGGLUTINATION
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
JP7097433B2 (ja) 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
MXPA04011679A (es) 2002-05-29 2005-03-07 Regeneron Pharma Sistema de expresion eucariotico inducible.
CA2496897C (en) 2002-08-30 2012-01-31 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
NZ544335A (en) 2003-06-11 2009-01-31 Biogen Idec Inc Method to increase protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005094355A2 (en) 2004-03-31 2005-10-13 Centocor, Inc. Methods for altering protein production rates
NZ552957A (en) * 2004-07-20 2011-06-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
US7514237B2 (en) * 2004-09-02 2009-04-07 Wyeth Systems and methods for protein production
WO2006031931A2 (en) 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
US8546126B2 (en) 2007-03-21 2013-10-01 Danisco Us Inc. Over expression of foldases and chaperones improves protein production
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009062789A1 (en) * 2007-11-13 2009-05-22 Boehringer Ingelheim Pharma Gmbh & Co Kg Improving the secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2009155008A1 (en) 2008-05-28 2009-12-23 Bayer Healthcare Llc Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法

Also Published As

Publication number Publication date
EP2875047A1 (en) 2015-05-27
BR112014029095A2 (pt) 2017-07-18
ES2940900T3 (es) 2023-05-12
EP4219546A2 (en) 2023-08-02
EP3564262A1 (en) 2019-11-06
HUE061479T2 (hu) 2023-07-28
JP2022044609A (ja) 2022-03-17
US9382315B2 (en) 2016-07-05
KR102663134B1 (ko) 2024-05-03
US9228012B2 (en) 2016-01-05
TW201823460A (zh) 2018-07-01
IL235573A0 (en) 2015-01-29
JP2018108094A (ja) 2018-07-12
US9079954B2 (en) 2015-07-14
JP2023153268A (ja) 2023-10-17
SG10201606654XA (en) 2016-10-28
US10227401B2 (en) 2019-03-12
AU2013267525B2 (en) 2017-11-16
US9193786B2 (en) 2015-11-24
US10611831B2 (en) 2020-04-07
MX360359B (es) 2018-10-30
MX2014014630A (es) 2015-02-12
KR102346867B1 (ko) 2022-01-04
CN104350068B (zh) 2019-12-03
AU2019203780A1 (en) 2019-06-20
WO2013181253A1 (en) 2013-12-05
KR102528950B1 (ko) 2023-05-08
CA2873131A1 (en) 2013-12-05
JP7037535B2 (ja) 2022-03-16
US10351622B2 (en) 2019-07-16
JP7382383B2 (ja) 2023-11-16
KR102126210B1 (ko) 2020-06-25
AU2021240303A1 (en) 2021-10-28
US20150353634A1 (en) 2015-12-10
EA201492242A1 (ru) 2015-05-29
FI2875047T3 (fi) 2023-03-30
US20150299310A1 (en) 2015-10-22
AU2018201094B2 (en) 2019-06-20
JP6298455B2 (ja) 2018-03-20
JP6622334B2 (ja) 2019-12-18
US20190270800A1 (en) 2019-09-05
IL265867A (en) 2019-06-30
US20160304598A1 (en) 2016-10-20
USRE48651E1 (en) 2021-07-20
AU2018201094A1 (en) 2018-03-15
EP4219546A3 (en) 2023-08-23
EP2875047B1 (en) 2023-01-25
CN104350068A (zh) 2015-02-11
US20150175688A1 (en) 2015-06-25
KR20230065370A (ko) 2023-05-11
US9688751B2 (en) 2017-06-27
KR20220003165A (ko) 2022-01-07
US20130323788A1 (en) 2013-12-05
IL279922A (en) 2021-03-01
EA028790B1 (ru) 2017-12-29
ZA201408289B (en) 2016-09-28
KR20200074273A (ko) 2020-06-24
AU2013267525A1 (en) 2014-12-11
JP2015518728A (ja) 2015-07-06
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
AU2019203780B2 (en) 2021-07-01
TW201402815A (zh) 2014-01-16
JP2020022514A (ja) 2020-02-13
EA201792213A1 (ru) 2018-01-31
SG11201407652RA (en) 2014-12-30
DK2875047T3 (da) 2023-03-27
US20150299309A1 (en) 2015-10-22
IL235573B (en) 2019-09-26
KR20150015492A (ko) 2015-02-10
US20170291938A1 (en) 2017-10-12
CN110835624A (zh) 2020-02-25

Similar Documents

Publication Publication Date Title
HK1211623A1 (zh) 細胞系
GB201301173D0 (en) Object production
EP2725091A4 (en) DEVICE FOR PRODUCING A CELL STRUCTURE
AU347859S (en) Battery
AU346864S (en) Battery
EP2824749A4 (en) BATTERY WITH A COATED STRUCTURE
EP2911230A4 (en) CELL
IL279922A (en) Amplifiers of production cell lines
EP2939306A4 (en) DRUMS
SG11201500417PA (en) Cell culture
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2898114A4 (en) HYDROGEN PRODUCTION
AU2013200983B9 (en) Hydrogen production
EP2830138A4 (en) BIO FUEL CELL
EP2922109A4 (en) SOLAR CELL
EP2863459A4 (en) FLAT CELL
EP2939294A4 (en) DRUMS
EP2804221A4 (en) CIGS COMPOUND SOLAR BATTERY
EP2874200A4 (en) FLAT BATTERY
SG11201405540QA (en) A cell arrangement
EP2919288A4 (en) SOLAR CELL
GB201211873D0 (en) Cell culture
EP2911227A4 (en) FLAT BATTERY
GB201218045D0 (en) Battery
GB201104761D0 (en) Biodiesel production

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: 29.05.2013 US,13/904,587